Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ECRG4 as a novel diagnostic plasma marker detected in the early phase of Alzheimer’s disease

ABSTRACT: Current therapeutic methods for Alzheimer’s disease (AD) aim to delay its progression; therefore, developing a reliable method for diagnosing the early phases of the disease (EAD) is crucial. Based on the finding that the secretory protein Esophageal Cancer-Related Gene 4 (ECRG4) is elevated in the hippocampus of AD patients, we developed a new ECRG4 ELISA system. Here, we show that ECRG4 peptides, particularly those containing amino acids 108 to 132, are increased in the plasma of approximately 25% of mild cognitive impairment and half of AD patients, compared to non-dementia individuals. RNA sequencing analysis of the plasma revealed decreased levels of CHST3 mRNA, which is highly expressed in oligodendrocyte-lineage cells, in ECRG4-positive patients. We demonstrate that amino acids 71 to 107 exert cytotoxicity to oligodendrocytes in culture and decrease the intensity of the oligodendrocyte marker in the corpus callosum when injected into the brain. This results in extravascular IgG leakage due to the accumulation of oligodendrocyte precursor cells (OPCs), which regenerate myelin, around the blood vessels. Given that similar phenomena were detected in the brains of EAD patients, these results suggest that ECRG4 is involved in the progression of AD through vascular destruction in a manner dependent on oligodendrocyte defects.

ORGANISM(S): Homo sapiens

PROVIDER: GSE299804 | GEO | 2025/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression profiles of Ecrg4-treated mouse microglia

Project description:Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Using the mouse glioma–initiating cell models, we identified Ecrg4 acts as a tumor suppressor in vivo. To characterize the function of Ecrg4 towards microglia, an innate immune cell in central nervous system, we performed gene expression microarray analysis for primary microglia treated with or without recombinant Fc-fused Ecrg4 fragments. We demonstrate here that Ecrg4 fragments, amino acid residues 71-132 and 133-148, which are produced by the proteolitic cleavage, induced the expression of pro-inflammatory cytokines in microglia. Thus, Ecrg4 acts as a cytokine/chemokine inducer, which activates the immune cells to eradicate tumor.

2016-09-28 | GSE87376 | GEO

Gene expression profile of Ba/F3 variant (#BEB1) cells that have binding ability to Ecrg4

Project description:Esophageal cancer-related gene 4 (Ecrg4) encodes a hormone-like peptide, and is thought to be involved in a variety of physiological phenomena including tumor suppressor function. Recent progress of Ecrg4 reveals that Ecrg4 peptides are pro-inflammatory and induce the expression of several cytokines and chemokines. However, detailed molecular mechanisms of Ecrg4 signaling, especially the receptors for Ecrg4 peptides, remain poorly understood. Here, using retrovirus-mediated expression cloning, we identified lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) as a membrane protein bound for amino acid residues 71-132 of Ecrg4, Ecrg4(71-132). Moreover, not only LOX-1 but also several scavenger receptors such as Scarf1, Cd36 and Stabilin-1 efficiently internalized Ecrg4(71-132) into cells. The broad scavenger receptor competitive inhibitor polyinosinic acid reduced both the internalization of Ecrg4(71-132) and activation of NF-kB in microglia. In addition, this activation is dependent on Myd88, an adaptor protein to recruit signaling proteins to TLR and IL-1R receptors with induction of several immune response. These data suggest that multiple scavenger receptors recognize Ecrg4(71-132) and transduce its signals along with TLR/IL-1R receptors in microglia.

2018-03-23 | GSE106400 | GEO

Down-regulation of ECRG4, a candidate tumor suppressor gene in human breast cancer

Project description:ECRG4 is a promising tumor suppressor gene (TSG) recently identified in esophageal carcinoma. Its expression and prognostic value have never been explored in breast cancer. Using DNA microarray, we examined ECRG4 mRNA expression in 353 invasive breast cancer samples. A meta-analysis was performed on a large public retrospective gene expression dataset (n=1,387) to analyze correlation between ECRG4 expression and histo-clinical features including survival.

2011-12-02 | GSE31448 | GEO

Gene expression profiles of Ecrg4-wt, -hetero and -homo NSCs

Project description:To identify factors that increase and decrease in Ecrg4 deficient NSCs

2019-02-27 | GSE120749 | GEO

Cell-free transcriptome of Barrett’s Esophagus and Esophageal Cancer [Illumina - short read]

Project description:Esophageal adenocarcinoma (EAD) benefits from a large improvement in five-year survival when detected in early stages, therefore, early detection strategies are paramount to mitigating disease. Those diagnosed with Barrett’s Esophagus (BE) are at higher risk for EAD, though there exists no routine screening for EAD. Recent advances in cell-free RNA sequencing aim to create minimally-invasive diagnostic modalities. We present short and long read data from plasma of BE, EAD, and Healthy patients for biomarker discovery.

2025-12-08 | GSE271390 | GEO

Cell-free transcriptome of Barrett’s Esophagus and Esophageal Cancer [Nanopore - long read]

2025-12-08 | GSE271389 | GEO

A single-cell landscape of human liver transplantation reveals a pathogenic immune niche associated with early allograft dysfunction

Project description:Liver transplantation (LT) is the standard therapy for individuals afflicted with end-stage liver disease. Despite notable advancements in LT technology during recent decades, the incidence of early allograft dysfunction (EAD) remains a critical concern, exacerbating the current organ shortage and detrimentally affecting the prognosis of recipients. Unfortunately, the perplexing hepatic heterogeneity has impeded our comprehension of the cellular traits and molecular events that contribute to EAD. Herein, we constructed the pioneering single-cell transcriptomic landscape of human transplanted livers derived from non-EAD and EAD patients, with 12 liver samples from 7 donors collected at the stages of cold perfusion and portal reperfusion. By comparing 75,231 cells of non-EAD and EAD patients, we identified an EAD-associated immune niche comprising MAIT, GZMB+ GZMK+ NK cells, and S100A12+ neutrophils, which were significantly elevated in EAD patients. Moreover, we verified this immune niche and its association with EAD occurrence in two independent cohorts. Our findings clarified the cellular characteristics of transplanted livers and the EAD-associated pathogenic immune niche at the single-cell level, offering valuable insights into the EAD onset. The updated data see FigShare (https://figshare.com/articles/dataset/24521662)

2021-12-16 | GSE189539 | GEO